Get the Stockscreener App
19.17
5.16%
0.94
After Hours:
19.17
Amarin Corp Adr stock is traded at $19.17, with a volume of 85,767.
It is up +5.16% in the last 24 hours and up +27.71% over the past month.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
See More
Previous Close:
$18.23
Open:
$18.58
24h Volume:
85,767
Relative Volume:
1.13
Market Cap:
$396.49M
Revenue:
$306.91M
Net Income/Loss:
$-59.11M
P/E Ratio:
-127.80
EPS:
-0.15
Net Cash Flow:
$6.35M
1W Performance:
-0.83%
1M Performance:
+27.71%
6M Performance:
+106.13%
1Y Performance:
+62.46%
1-Day Range:
$18.58
$19.52
1-Week Range:
$18.01
$20.43
52-Week Range:
$7.08
$20.43
Amarin Corp Adr Stock (AMRN) Company Profile
Name
Amarin Corp Adr
Sector
Industry
Phone
353 1 6699 020
Address
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
19.17 | 377.05M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
819.40 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.90 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
230.30 | 407.19B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.12 | 251.72B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.70 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Oct-25-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| May-06-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-04-22 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-12-21 | Downgrade | Goldman | Neutral → Sell |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| May-05-20 | Initiated | Northland Capital | Outperform |
| Mar-31-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-31-20 | Upgrade | Oppenheimer | Underperform → Perform |
| Mar-13-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-02-20 | Initiated | Cowen | Outperform |
| Feb-18-20 | Upgrade | Citigroup | Neutral → Buy |
| Jan-06-20 | Initiated | JP Morgan | Neutral |
| Dec-16-19 | Downgrade | Stifel | Buy → Hold |
| Nov-20-19 | Initiated | Oppenheimer | Underperform |
| Nov-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Nov-15-19 | Reiterated | SVB Leerink | Outperform |
| Oct-31-19 | Initiated | Aegis Capital | Buy |
| Oct-15-19 | Initiated | Goldman | Neutral |
| Aug-14-19 | Initiated | SVB Leerink | Outperform |
| Jul-09-19 | Reiterated | Jefferies | Buy |
| Jun-17-19 | Initiated | ROTH Capital | Buy |
| Mar-22-19 | Initiated | Stifel | Buy |
View All
Amarin Corp Adr Stock (AMRN) Latest News
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - Sahm
Amarin Corporation plc Announces $17.8 Million Registered Direct Offering of American Depositary Shares - ADVFN
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
3 Strong Buy Breakout Stocks for Explosive Returns - The Globe and Mail
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin licenses VAZKEPA to Recordati in 59 European countries - Investing.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Looking For A Top Momentum Stock? Check Out Amarin Corp ADR (NASDAQ: AMRN) - Stocksregister
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug - Stock Titan
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
How Amarin's Latest European Reimbursement Victory Strengthens Its Cardiovascular Market Position - Stock Titan
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Top 3 Health Care Stocks You'll Regret Missing In Q4Amarin Corp (NASDAQ:AMRN) - Benzinga
Amarin to present new cardiovascular research at ESC Congress - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Amarin's VAZKEPA gains reimbursement approval in Greece - Investing.com
Amarin secures new patent for heart drug VAZKEPA in Europe - Investing.com
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
股神出手｜畢菲特首度買進台積電ADR 涉逾41.2億美元 4家避險基金均增持台積電 - Yahoo 財經
Validea Kenneth Fisher Strategy Daily Upgrade Report9/24/2022 - Nasdaq
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics - Nasdaq
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan - The Globe and Mail
AMRNAmarin Latest Stock News & Market Updates - Stock Titan
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval - MarketWatch
Heart Drugs Are Having a Moment - Bloomberg.com
Amarin Corp PLC (AMRN) Stock Price, Trades & News - GuruFocus
Fish-Oil Heart Medicine Is Rarest of Drug Breakthroughs - Bloomberg
Amarin Corp Adr Stock (AMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):